Interpace Biosciences®, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Fair Value Measurements (Tables)

Fair Value Measurements (Tables)

12 Months Ended

Dec. 31, 2020

Schedule of Financial Instrument Measured on Recurring Basis

The valuation methodologies used for the Company’s financial instruments measured on a recurring basis at fair value, including the general classification of such instruments pursuant to the valuation hierarchy, is set forth in the tables below.

	As of December 31, 2020				Fair Value Measurements
	Carrying		Fair		As of December 31, 2020
	Amount		Value		Level 1		Level 2		Level 3

Liabilities:
Contingent consideration:
Asuragen ⁽¹⁾	$	2,216	$	2,216	$	-	$	-	$	2,216
Other long-term liabilities:
Warrant liability ⁽²⁾		21		21		-		-		21
	$	2,237	$	2,237	$	-	$	-	$	2,237

	As of December 31, 2019				Fair Value Measurements
	Carrying		Fair		As of December 31, 2019
	Amount		Value		Level 1		Level 2		Level 3

Liabilities:
Contingent consideration:
Asuragen ⁽¹⁾	$	2,893	$	2,893	$	-	$	-	$	2,893
Other long-term liabilities:
Warrant liability ⁽²⁾		82		82		-		-		82
	$	2,975	$	2,975	$	-	$	-	$	2,975

Schedule of Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation

The fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement.

								Cancellation		Adjustment
								of Obligation/		to Fair Value/
	December 31, 2019		Payments			Accretion		Conversions Exercises		Mark to Market			December 31, 2020

Asuragen	$	2,893	$	(737	)	$	549	$	-	$	(489	)	$	2,216

Underwriters Warrants		82		-			-		-		(61	)		21
	$	2,975	$	(737	)	$	549	$	-	$	(550	)	$	2,237